Holen Sie sich die Stockscreener-App
2.83
5.67%
-0.17
Schlusskurs vom Vortag:
$3.00
Offen:
$3.03
24-Stunden-Volumen:
704.06K
Relative Volume:
0.45
Marktkapitalisierung:
$201.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-0.8576
EPS:
-3.3
Netto-Cashflow:
$-167.04M
1W Leistung:
+0.71%
1M Leistung:
-6.60%
6M Leistung:
+65.50%
1J Leistung:
+47.40%
1-Tages-Spanne:
$2.83
$3.0494
1-Wochen-Bereich:
$2.54
$3.0494
52-Wochen-Spanne:
$0.783
$3.39
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Firmenname
Ventyx Biosciences Inc
Sektor
Branche
Telefon
(858) 945-2393
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Vergleichen Sie VTYX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
2.83 | 213.93M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-03-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-11-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-19 | Eingeleitet | Goldman | Buy |
| 2022-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-07 | Eingeleitet | Stifel | Buy |
| 2022-09-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-09 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-02-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-15 | Eingeleitet | Jefferies | Buy |
| 2021-11-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten
Ventyx Biosciences Reports Decreased Losses in 2025 - MSN
Smart tools for monitoring Ventyx Biosciences Inc.’s price actionMarket Risk Analysis & Growth Focused Stock Reports - Newser
XTX Topco Ltd Sells 50,472 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences Inc. stock prediction for this weekWeekly Trade Recap & Real-Time Stock Movement Alerts - Newser
How institutional ownership impacts Ventyx Biosciences Inc. stockJuly 2025 Weekly Recap & Weekly High Potential Alerts - Newser
Full technical analysis of Ventyx Biosciences Inc. stockPortfolio Risk Report & Weekly Chart Analysis and Trade Guides - Newser
Ventyx Biosciences Reports Q2 2025 Earnings: Decreased Losses and Improved Cash Position - AInvest
What MACD signals say about Ventyx Biosciences Inc.2025 Market WrapUp & Verified Momentum Stock Watchlist - Newser
Can Ventyx Biosciences Inc. lead its sector in growthJuly 2025 Update & Free Technical Pattern Based Buy Signals - sundaytimes.kr
Is Ventyx Biosciences Inc. the Top Chart Pick This WeekTrade Performance Summary & Free Community Supported Trade Ideas - sundaytimes.kr
What recovery options are there for Ventyx Biosciences Inc.Earnings Summary Report & Real-Time Sentiment Analysis - Newser
Will Ventyx Biosciences Inc. rebound enough to break evenQuarterly Earnings Summary & Real-Time Volume Surge Alerts - Newser
Ventyx Biosciences Inc. Stock Approaches Key Moving AverageWeekly Market Summary & Entry Point Confirmation Alerts - beatles.ru
Will Ventyx Biosciences Inc. stock go up soon2025 Top Decliners & Technical Buy Zone Confirmations - Newser
What MACD and RSI say about Ventyx Biosciences Inc.Recession Risk & Daily Growth Stock Investment Tips - Newser
Tools to monitor Ventyx Biosciences Inc. recovery probabilityWeekly Volume Report & Daily Price Action Insights - Newser
Ventyx Biosciences Inc. stock chart pattern explainedVolume Spike & Community Verified Swing Trade Signals - Newser
Published on: 2025-08-12 23:04:56 - Newser
Has Ventyx Biosciences Inc. Stock Ever Crashed Historical Volatility ReviewValue Holding Return Summary With Outlook - Newser
What technical models suggest about Ventyx Biosciences Inc.’s comebackTrend Reversal & AI Forecast Swing Trade Picks - Newser
Can Ventyx Biosciences Inc Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Detecting support and resistance levels for Ventyx Biosciences Inc.Weekly Outlook for Short Term Investors - Newser
Building trade automation scripts for Ventyx Biosciences Inc.Free Weekly Stock Opportunity Radar Scanner - Newser
A Quick Look at Today's Ratings for Ventyx Biosciences(VTYX.US), With a Forecast Between $9 to $21 - 富途牛牛
Ventyx Biosciences Earns Buy Rating: Analyst Cites Promising Developments - AInvest
Real time social sentiment graph for Ventyx Biosciences Inc.Chart Pattern Recognition for Profit Timing - Newser
H.C. Wainwright Keeps Their Hold Rating on Ventyx Biosciences (VTYX) - The Globe and Mail
Wall Street Zen Upgrades Ventyx Biosciences (NASDAQ:VTYX) to “Hold” - Defense World
Why Ventyx Biosciences Inc. stock attracts strong analyst attentionFree Oversold Recovery Opportunity Stocks - Newser
Is Ventyx Biosciences Inc. forming a bottoming baseChart Scanner for Swing Trade Timing - Newser
Applying big data sentiment scoring on Ventyx Biosciences Inc.Entry Zone Watchlist With Momentum Focus - Newser
Ventyx Biosciences shares surge 12.50% intraday after reporting better-than-expected Q2 earnings and positive biomarker data for VTX3232 in Parkinson's treatment. - AInvest
Ventyx Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ventyx Biosciences Q2 2025 Earnings Beat Estimates, Cash Position at $209M - AInvest
Ventyx (VTYX) Q2 Net Loss Drops 16% - The Globe and Mail
Ventyx Biosciences Q2 GAAP EPS of -$0.38 Beats Expectations - AInvest
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress - GlobeNewswire
Ventyx Biosciences Q2 FY25 Revenue $5.4mln, Cash Balance $209mln. - AInvest
Ventyx Breakthrough: Phase 2 Parkinson's Drug Shows Promise, Plus Two Major Trial Results Expected in Q4 2025 - Stock Titan
What candlestick patterns are forming on Ventyx Biosciences Inc.Free Accurate Buy Point for Momentum Stocks - Newser
Ventyx Biosciences (VTYX) Projected to Post Earnings on Thursday - Defense World
Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):